Accessibility settings

This paper is in the following e-collection/theme issue:

Non-randomized Protocols and Methods (ehealth) (1063) Diabetes (335)

Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34206, first published .
Pharmacist's hand reaching for medication box on a shelf in a pharmacy.

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study)

Authors of this article:

Michael Feher1 Author Orcid Image ;   William Hinton1 Author Orcid Image ;   Anna Forbes1 Author Orcid Image ;   Neil Munro2 Author Orcid Image ;   Mark Joy1 Author Orcid Image ;   David Wheeler3 Author Orcid Image ;   Simon de Lusignan1 Author Orcid Image
Article Authors Cited by (1) Tweetations (3) Metrics

Journals

  1. Hinton W, Joy M, Forbes A, Whyte M, Ordóñez‐Mena J, Fan X, Ferreira F, Meza‐Torres B, Munro N, de Lusignan S, Wheeler D, Feher M. Combining Sodium–Glucose Co‐Transporter‐2 Inhibitor Plus Glucagon‐Like Peptide‐1 Receptor Agonist for Glucose‐Lowering in Type 2 Diabetes: Effects of Drug Initiation Sequence on Kidney Function in Real‐World Clinical Practice (CombiKid Study). Diabetes, Obesity and Metabolism 2026 View